Find Us on Facebook Follow Us on Twitter Find Us on Youtube Bookmark & Share Subscribe to Feed

Cancer Research: Diabetes and cancer: 5 years into the recent controversy.


http:  linkinghub.elsevier.com ihub images PubMedLink Cancer Research: Diabetes and cancer: 5 years into the recent controversy. Related Articles

Diabetes and cancer: 5 years into the recent controversy.

Eur J Cancer. 2014 Aug;50(12):2119-25

Authors: Badrick E, Renehan AG

Abstract
Diabetes and cancer are common chronic disorders. The literature has long recognised that type 2 diabetes (T2D) is associated with an increased incident risk of several cancer types, independent of the mutual risk factor, obesity. However, in June 2009, four papers were published simultaneously in Diabetologia, the official journal of the European Association for the Study of Diabetes, raising questions of a link between diabetes therapies, notably the long-acting insulin analogue, glargine, and increased cancer risk. These papers awakened an unprecedented debate in the diabetes community, drawing in cancer experts and bringing together representatives from these two large, traditionally non-intersecting, biomedical communities. This Current Perspective summarises the events that followed the ‘breaking news’ from summer 2009: the pitfalls encountered; the increased mutual understanding between diabetes and cancer researchers; and the direction of current research. Much of the debate on the clinical impact of this controversy has been played out in the diabetes literature: here, we update the oncology readership.

PMID: 24930060 [PubMed - indexed for MEDLINE]

pubmed: clinical cancer rese…

Cancer Research: Selenium supranutrition: are the potential benefits of chemoprevention outweighed by the promotion of diabetes and insulin resistance?


http:  www.pubmedcentral.nih.gov corehtml pmc pmcgifs pubmed pmc Cancer Research: Selenium supranutrition: are the potential benefits of chemoprevention outweighed by the promotion of diabetes and insulin resistance? Related Articles

Selenium supranutrition: are the potential benefits of chemoprevention outweighed by the promotion of diabetes and insulin resistance?

Nutrients. 2013;5(4):1349-65

Authors: Rocourt CR, Cheng WH

Abstract
Selenium was considered a toxin until 1957, when this mineral was shown to be essential in the prevention of necrotic liver damage in rats. The hypothesis of selenium chemoprevention is principally formulated by the observations that cancer incidence is inversely associated with selenium status. However, recent clinical and epidemiological studies demonstrate a role for some selenoproteins in exacerbating or promoting other disease states, specifically type 2 diabetes, although other data support a role of selenium in stimulating insulin sensitivity. Therefore, it is clear that our understanding in the role of selenium in glucose metabolism and chemoprevention is inadequate and incomplete. Research exploring the role of selenium in individual healthcare is of upmost importance and possibly will help explain how selenium is a double-edged sword in the pathologies of chronic diseases.

PMID: 23603996 [PubMed - indexed for MEDLINE]

pubmed: clinical cancer rese…

Cancer News: Roche halts diabetes drug trial in blow to pipeline


ZURICH (Reuters) – Roche will halt development of a diabetes drug partly because of its undesired side-effects, marking another high-profile setback for the Swiss company as it struggles to diversify outside its core cancer drug portfolio.mf Cancer News: Roche halts diabetes drug trial in blow to pipeline

 Cancer News: Roche halts diabetes drug trial in blow to pipeline  Cancer News: Roche halts diabetes drug trial in blow to pipeline  Cancer News: Roche halts diabetes drug trial in blow to pipeline

 Cancer News: Roche halts diabetes drug trial in blow to pipeline
Reuters: Health News

Cancer News: Drugmakers to cooperate in safety review of diabetes drugs


NEW YORK (Reuters) – Global drugmakers said on Wednesday they would cooperate with an independent review to address concerns of a potential link between widely used diabetes medicines and pancreatic cancer and other safety problems.mf Cancer News: Drugmakers to cooperate in safety review of diabetes drugs

 Cancer News: Drugmakers to cooperate in safety review of diabetes drugs  Cancer News: Drugmakers to cooperate in safety review of diabetes drugs  Cancer News: Drugmakers to cooperate in safety review of diabetes drugs

 Cancer News: Drugmakers to cooperate in safety review of diabetes drugs
Reuters: Health News

Cancer Research: Diabetes and pancreatic cancer.


Related Articles

Diabetes and pancreatic cancer.

Minerva Gastroenterol Dietol. 2012 Dec;58(4):331-45

Authors: Muniraj T, Chari ST

Abstract
The relationship between diabetes and pancreatic cancer is complex. Diabetes or impaired glucose tolerance is present in more than 2/3rd of pancreatic cancer patients. Epidemiological studies have consistently shown a modest increase in the risk of pancreatic cancer in type 2 diabetes, with an inverse relationship to duration of disease. Additionally, recent studies suggest that anti-diabetic medications may modulate the risk of pancreatic cancer in type 2 diabetes. Subjects >50 years of age with new onset diabetes are at higher risk of having pancreatic cancer. However, to screen new-onset diabetes for pancreatic cancer, additional markers are needed that can distinguish pancreatic cancer-associated diabetes from type 2 diabetes.

PMID: 23207610 [PubMed - indexed for MEDLINE]

pubmed: clinical cancer rese…